NO20060976L - Vaksine - Google Patents

Vaksine

Info

Publication number
NO20060976L
NO20060976L NO20060976A NO20060976A NO20060976L NO 20060976 L NO20060976 L NO 20060976L NO 20060976 A NO20060976 A NO 20060976A NO 20060976 A NO20060976 A NO 20060976A NO 20060976 L NO20060976 L NO 20060976L
Authority
NO
Norway
Prior art keywords
rotavirus
vaccine
serotype
eliciting
administering
Prior art date
Application number
NO20060976A
Other languages
English (en)
Other versions
NO342397B1 (no
Inventor
Brigitte Desiree Alberte Colau
Beatrice Arsene Virginie D Vos
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0414787.2A external-priority patent/GB0414787D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20060976L publication Critical patent/NO20060976L/no
Publication of NO342397B1 publication Critical patent/NO342397B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oppfinnelsen tilveiebringer en fremgangsmåte for fremkalling av en immunrespons mot rotavirusinfeksjon med én rotavirus-serotype, idet fremgangsmåten omfatter administrering av et preparat omfattende en svekket rotavirusvaksine fra en annen serotype, til et individ.
NO20060976A 2003-09-02 2006-02-28 Anvendelse av en attenuert human rotavirusstamme fra en G1 serotype for fremstilling av en sammensetning for indusering av en immunrespons NO342397B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49943003P 2003-09-02 2003-09-02
GBGB0414787.2A GB0414787D0 (en) 2004-07-01 2004-07-01 Method
PCT/EP2004/009725 WO2005021033A2 (en) 2003-09-02 2004-08-31 Vaccine

Publications (2)

Publication Number Publication Date
NO20060976L true NO20060976L (no) 2006-03-31
NO342397B1 NO342397B1 (no) 2018-05-14

Family

ID=34276843

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060976A NO342397B1 (no) 2003-09-02 2006-02-28 Anvendelse av en attenuert human rotavirusstamme fra en G1 serotype for fremstilling av en sammensetning for indusering av en immunrespons

Country Status (17)

Country Link
EP (2) EP1660123B1 (no)
JP (1) JP5588586B2 (no)
KR (1) KR20060126917A (no)
AU (1) AU2004268375B2 (no)
BR (1) BRPI0414073A (no)
CA (1) CA2536734C (no)
HR (2) HRP20130407T1 (no)
IL (1) IL173921A0 (no)
IS (1) IS2922B (no)
MA (1) MA28035A1 (no)
MX (1) MXPA06002459A (no)
NO (1) NO342397B1 (no)
NZ (1) NZ545639A (no)
PL (2) PL2272532T3 (no)
RU (1) RU2368392C2 (no)
SG (1) SG147465A1 (no)
WO (1) WO2005021033A2 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080036648A (ko) * 2005-08-17 2008-04-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 이형 교차 방어를 유도하는 로타바이러스 백신
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
WO2011138229A1 (en) * 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
US9045728B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Liquid viral formulations
WO2012075376A2 (en) * 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine
US10550405B2 (en) 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
CN117535247A (zh) * 2018-05-07 2024-02-09 北卡罗来纳-查佩尔山大学 合理的多倍体腺相关病毒载体及其制造和使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
KR0171434B1 (ko) * 1990-11-16 1999-02-01 윌리엄 케이. 슈버트 인체 로타바이러스, 백신 및 방법
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
AR029643A1 (es) * 1999-08-17 2003-07-10 Smithkline Beecham Biolog Poblacion de rotavirus atenuados, variantes y recombinantes de dichos rotavirus atenuados, metodo para producir dichas poblaciones de rotavirus purificadas, composiciones de vacunas que comprenden dichos virus atenuados, vivos, metodo para obtener dichas vacunas y un metodo para prevenir en el hombr

Also Published As

Publication number Publication date
SG147465A1 (en) 2008-11-28
AU2004268375A1 (en) 2005-03-10
CA2536734C (en) 2014-07-08
EP2272532B1 (en) 2016-02-10
JP2007516215A (ja) 2007-06-21
RU2006106427A (ru) 2007-10-10
KR20060126917A (ko) 2006-12-11
MXPA06002459A (es) 2006-06-20
IS2922B (is) 2015-04-15
CA2536734A1 (en) 2005-03-10
WO2005021033A2 (en) 2005-03-10
NZ545639A (en) 2009-04-30
PL2272532T3 (pl) 2016-07-29
AU2004268375B2 (en) 2010-01-28
NO342397B1 (no) 2018-05-14
BRPI0414073A (pt) 2006-10-24
HRP20130407T1 (en) 2013-06-30
WO2005021033A3 (en) 2005-05-06
EP2272532A3 (en) 2012-08-01
EP1660123B1 (en) 2013-03-13
EP1660123A2 (en) 2006-05-31
HRP20160299T1 (hr) 2016-04-22
PL1660123T3 (pl) 2013-08-30
JP5588586B2 (ja) 2014-09-10
EP2272532A2 (en) 2011-01-12
IL173921A0 (en) 2006-07-05
MA28035A1 (fr) 2006-07-03
RU2368392C2 (ru) 2009-09-27
IS8325A (is) 2006-02-23

Similar Documents

Publication Publication Date Title
NO20060976L (no) Vaksine
DK1863526T3 (da) Levende, attenueret rotavirusvaccine til oral indgivelse
CY2013036I2 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
EP1708749A4 (en) MUCOSAL VACCINE ADJUVANTS CONTAINING BACTERIAL FLAGELLINS AS AN ACTIVE COMPONENT
WO2007092792A3 (en) Yeast-based vaccine for inducing an immune response
ATE426412T1 (de) Adjuvante influenza-vakzine
BRPI0519000A2 (pt) variantes de il-7 com imunogenicidade reduzida
NO20052149D0 (no) Vaksine.
EP2601969A3 (en) Norovirus vaccine formulations
NO20064034L (no) Makrolider og fremgangsmater for a fremstille disse
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
WO2006055024A3 (en) Minicells as vaccines
ATE269104T1 (de) Salmonella impfstoff, der keinen antikörper gegen flagellin oder gegen flagella induziert
CY1116135T1 (el) Εμβολιο ροταϊου που διεγειρει ετεροτυπικη εγκαρσια προστασια
FR2922767B1 (fr) Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
ATE526034T1 (de) Verbesserte inaktivierte fcv-vakzinen
WO2003060088A3 (en) Viral vaccine production method
WO2006100430A3 (en) Polypeptides
WO2007070678A3 (en) Rabies vaccine
WO2010080188A3 (en) Epitope targeted anthrax vaccine
WO2006088997A3 (en) Adjuvant activities of b pentamers of lt-iia and lt-iib enterotoxin
ES2365717T5 (es) Vacunacion meningococica conjugada.
CY1114309T1 (el) Εμβολιο ροταϊου
WO2004083390A3 (en) Virulent systemic feline calicivirus
DE602004019971D1 (de) Kombinationsvakzine für geflügel